New drug combo aims to shrink melanoma before surgery
NCT ID NCT07527325
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving two immunotherapy drugs (fianlimab and cemiplimab) before surgery can shrink melanoma tumors in people with stage IIIB to IV melanoma. About 35 adults will receive the drugs, then have surgery to remove any remaining cancer. The main goal is to see how many patients have a major or complete response in their tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Chao Family Comprehensive Cancer Center University of California, Irvine
Orange, California, 92868, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- E-Learning could sharpen Doctors' eye for skin cancer
- Can a new drug tame advanced solid tumors?
- Can a short Pre-Surgery immunotherapy course replace Long-Term adjuvant treatment for melanoma?
- Can a single tracer light up cancer's first stop? a trial puts a hybrid dye-and-radioactive marker to the test.
- Could a Two-Drug combo reawaken the immune system against resistant cancers?
- Astrophysics meets dermatology: AI that maps moles like stars to catch melanoma early